PCDI 2025 Patient Survey: Now Open

The Patient-Centered Dosing Initiative (PCDI)—an MBC patient-led effort—is conducting a new survey about treatment dosing and side effects.

This survey is intended for individuals in the United States who have been diagnosed with metastatic breast cancer.

📬 Links to the survey are being distributed privately.


Participation is voluntary, and you may exit the survey at any time. All collected information is anonymized and kept confidential.

About the Survey
The Patient-Centered Dosing Initiative (PCDI)—led by MBC patients like you—invites you to participate in a research study on MBC treatment dosing and side effects. Your experiences are invaluable and will help us identify opportunities to improve the treatment journey for our community.

Why Participate?
Your input builds on our groundbreaking 2020 research, which helped bring personalized dosing into the conversation.
Your responses remain anonymous, and you have full control over what you share.
Results may be presented at conferences, published in scientific journals, and shared on our website.

What’s Involved?
A short online survey (about 20 minutes).
Sharing your thoughts on MBC treatment, side effects, dosing, and decision-making confidence.

Important Details
Participation is voluntary, and you may exit the survey at any time.
All collected information is kept confidential.

PAST SURVEYS

Patient Survey (2020)

The Patient-Centered Dosing Initiative (PCDI) conducted the MBC Patient Survey to better understand the impact of treatment-related side effects on individuals with metastatic breast cancer (MBC). Designed by MBC patient advocates, the survey explored the prevalence and severity of side effects, communication between patients and doctors, and the potential benefits of personalized dosing strategies.

The results were striking: 86% of the 1,221 respondents reported experiencing at least one significant side effect. These side effects were severe enough to result in hospital visits for 1 in 5 patients, and more than 40% missed at least one treatment. Despite these challenges, 92% of patients expressed a willingness to discuss flexible dosing options with their oncologists, highlighting a strong interest in approaches that could improve both quality of life and treatment adherence.

Medical Oncologists Survey (2021)

Building on the success of the patient survey, PCDI launched the Medical Oncologists Survey in 2021 to gain insights into oncologists’ perspectives. The results revealed that oncologists often underestimated the prevalence and severity of side effects experienced by their patients. However, 85% did not believe that higher doses were always more effective, and 97% were open to discussing flexible dosing options with their patients.

Together, these surveys are fostering critical conversations and driving change in oncology care.

Recognized Impact and Success

Anne Loeser, the visionary founder of PCDI, giving an oral presentation at ASCO 2021 on the patient survey.

The insights from the PCDI’s patient and oncologist surveys have gained widespread recognition, sparking critical conversations and driving tangible change in cancer care. The Patient Survey results were presented globally at the American Society of Clinical Oncology (ASCO) 2021 conference, with additional highlights shared at "Best of ASCO" Malaysia.

Janice Cowden, a senior member of the PCDI team, presented the results of the oncologist survey at SABCS 2021.

This international exposure amplified patient voices and underscored the importance of addressing treatment-related side effects.

The Medical Oncologists Survey further solidified PCDI’s impact, with its findings published in the peer-reviewed journal Breast Cancer Research and Treatment. The results were also featured at the San Antonio Breast Cancer Symposium (SABCS) 2021 and summarized in the Journal of Clinical Pathways. Collectively, these surveys have been highlighted in multiple academic and clinical platforms, including a comprehensive paper in Clinical Trials summarizing PCDI’s groundbreaking work.

Publications and Presentation Materials

The insights from both surveys have been published in leading journals: